BMJ Open

Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk

Gillian G W Adams,1 Catey Bunce,1 Wen Xing,1 Lucilla Butler,2 Vernon Long,3 Aravind Reddy,4 Annegret H Dahlmann-Noor1

ABSTRACT

Objectives: To estimate the incidence of severe retinopathy of prematurity (ROP) requiring treatment and describe current treatment patterns in the UK.

Design: Nationwide population-based case ascertainment study via the British Ophthalmic Surveillance Unit and a national collaborative ROP special interest group. Practitioners completed a standardised case report form (CRF).

Setting: All paediatric ophthalmologists providing screening and/or treatment for retinopathy in the UK were invited to take part.

Participants: Any baby with ROP treated or referred for treatment between 1 December 2013 and 30 November 2014, treated with laser, cryotherapy, vascular endothelial growth factor (VEGF) inhibitor or vitrectomy/scleral buckling, or a combination.

Main outcome measure: Incidence of ROP requiring treatment.

Results: We received 370 CRFs; 327 were included. Denominator from epidemiological data: 8112 infants with birth weight of <1500 g. The incidence of ROP requiring treatment was 4% (327/8112, 95% CI 3.6% to 4.5%). Median gestational age was 25 weeks (IQR 24.3–26.1), and median birth weight 706 g (IQR 620–821). Median age at first treatment was 80 days (IQR 71–96). 204 right eyes (62.39%) had type 1 ROP, and 27 (8.26%) had aggressive posterior ROP. Infants were also treated for milder disease: 9 (2.75%) right eyes were treated for type 2 ROP, and 74 (22.63%) for disease milder than type 1 with plus or preplus, which we defined here as ‘type 2 plus’ disease. First-line treatment was diode laser photoablation of the avascular retina in 90.5% and injection of VEGF inhibitor in 8%.

Conclusions: ROP treatment incidence in the UK is 2.5 times higher than previously estimated. 8% of treated infants receive intravitreal VEGF inhibitor, currently unlicensed. Research is needed urgently to establish safety and efficacy of this approach. Earlier treatment and increasing numbers of surviving premature infants require an increase in appropriate eye care facilities and staff.

Trial registration number: NCT02484989.

INTRODUCTION

Retinopathy of prematurity (ROP) is a potentially blinding condition typically affecting preterm neonates of low gestational age and low birth weight.1 ROP is a major cause of preventable blindness in children worldwide: of 15 million children born worldwide in 2010, an estimated 53 000 developed sight-threatening type ROP requiring treatment and 20 000 became blind or severely sight impaired.2 Two-thirds of children suffering sight loss from ROP live in middle-income and moderately developed countries, particularly Latin America.12 Incidence of blindness from ROP is lower in highly developed countries (3–13%), where risk factors such as oxygen supplementation and blood oxygen saturation are monitored meticulously, and minimal in poorly developed countries, where premature babies often do not survive.1 In highly and moderately developed countries, the incidence of ROP is increasing, as advances in neonatal management allow more premature infants to survive despite very low gestational age and birth weight.34

The current standard treatment for sight-threatening ROP is laser photoablation of the non-vascularised, immature retina. Treatment decisions are based on severity (stage 1–5 or an aggressive posterior form of...
the condition, aggressive posterior ROP (AP-ROP)) and location (zone 1–3) of the disease and retinal vascular changes (plus disease) as defined by the International Committee for the Classification of ROP.6 Early treatment is now recommended to avoid progression to sight-threatening complications; a clinical algorithm advocates treatment for ‘type 1’ or ‘high-risk prethreshold’ ROP, defined as ‘zone 1 stage 3 ROP with or without plus, or zone 1 stage 1/2 with plus, or zone 2 stage 2/3 with plus disease’.6 However, treatment is occasionally given for earlier forms of ROP, that is, ‘type 2’ or ‘low-risk prethreshold’ ROP (zone 1, stage 1 or 2 without plus, or zone 2, stage 3 without plus disease)6 and ‘mild ROP’ (milder than type 2).7

However, even with timely laser photoacoagulation, ROP results in unfavourable structural and visual outcomes in a small, but significant number of children.6 8 9 It usually requires intubation and sedation or general anaesthesia, which may not be safe in systemically unstable infants, and it irreversibly destroys the peripheral retina, reducing the peripheral visual field.

Following the successes in the treatment of age-related macular degeneration (AMD) and diabetic retinopathy, recombinant antibodies targeted against vascular endothelial growth factor (VEGF), injected into the vitreous cavity, have recently been used in addition to laser photocoagulation and as first-line monotherapy to treat the most severe forms of ROP.10 Neither ranibizumab nor bevacizumab is licensed for this indication, though ranibizumab is licensed for intravitreal injection in AMD and other retinal conditions. Despite being unlicensed,11 bevacizumab is in ophthalmic use, as it incurs only a fraction of the cost of ranibizumab while having equivalent efficacy.12

In ROP, reported benefits of VEGF inhibitors include fast regression of neovascularisation and plus disease, vascularisation of the peripheral retina and the lack of a need for general anaesthesia. However, local and systemic safety is unknown. In infants, VEGF is vital in directing the sequential and orderly development of blood vessels in the retina and systemically.13 14 After injection into the eye, these agents enter the systemic circulation, and there are concerns about dose and timing of administration and potential adverse events, ocular and systemic. Most studies reporting the use of VEGF inhibitors in ROP have used bevacizumab rather than ranibizumab, partly because the larger size of the molecule may make it less likely to induce systemic suppression of VEGF serum levels; there are, however, no pharmacokinetic data to support this concept.

The lack of central registries or databases for the treatment of ROP hampers the collection of information about current treatment patterns. To evaluate current practice patterns in the treatment of ROP in the UK, we set up a 1-year national surveillance project. The main objectives of this study are to determine the current incidence of ROP requiring treatment and current treatment preferences.

METHODS
We conducted a prospective epidemiological active surveillance study of ROP treatment in the UK.

Study population
The UK ROP screening guideline recommends screening of infants <1501 g birth weight and <32 weeks gestational age.15

As denominator, we identified the number of premature births with birth weight of <1500 g in the surveyed area from the Office for National Statistics of England and Wales, http://www.statistics.org.uk. Scotland and Northern Ireland do not report on birth weight, so we estimated the number of low-birthweight (LBW) babies in these areas by assuming that the proportion of live births who were LBW was the same as that observed in England. The latest available birth figures from the Office for National Statistics show that in 2014, there were 661 496 live births in England and 33 544 in Wales; of these, respectively, 6097 and 322 had a birth weight of <1500 g. The number of live births in Northern Ireland and Scotland was 24 394 and 56 725, respectively, so assuming a similar proportion of LBW babies as observed in England, would have resulted in 258 and 545 babies, respectively. The total number of live births with birth weight <1500 g would then be 8112.

Inclusion criteria: any baby with ROP treated or referred to another unit for treatment between 1 December 2013 and 30 November 2014, with treatment either in the form of laser therapy, cryotherapy, VEGF inhibitor or vitrectomy/scleral buckling, or a combination of these treatments.

Exclusion criteria: any infant not fulfilling the above inclusion criteria.

Data collection
Incident cases were identified through the existing reporting system set up by the British Ophthalmic Surveillance Unit (BOSU). From December 2013 to December 2014, BOSU mailed cards to all consultant ophthalmologists and associate specialists in the UK once a month, with an invitation to report new cases of treated ROP, defined as above. On receipt of case notifications, we mailed a standardised case report form (CRF) collecting clinical data to the reporting ophthalmologists. We also set up an electronic special interest group (SIG), through which clinicians could inform the research team directly of new cases and send completed CRFs.

Definition of ROP severity groups
The CRF asked clinicians to specify severity (stage) and location (zone) of ROP based on the International Classification of ROP (ICROP).5 6 We then categorised the data into levels of severity as defined in previous publications6 7 (table 1). However, not all possible scenarios of zone/stage/plus disease status are covered by these classifications. A particular problem is zone 3 disease with plus and zone 2 stage 1 with plus; we categorised these as ‘type 2 plus disease’, which is an addition to existing
classifications. A second problem is that preplus disease was not yet defined at the time of the ICROP when type 1 and type 2 disease were described. As preplus disease is considered to carry a high risk of progression, and as close monitoring is recommended, we also categorised cases of preplus disease as 'type 2 plus', with the exception of zone 1 stage 3 disease, which should be treated regardless of plus disease status and is categorised as type 1 disease (table 1).

Confounders
We reviewed data to exclude duplication of cases arising from children being transferred between neonatal units or consultants, and from reports received via BOSU and via the SIG routes.

Statistical analysis
Data from the CRFs were entered onto an electronic Red Cap (Research Electronic Data Capture) database. A random sample of forms were inspected to ensure data quality. After data lock, data were transferred into Stata V.13.0 for analysis. Characteristics of infants requiring ROP treatment were summarised using means and SDs for approximately Gaussian continuous variables and medians and IQRs for non-Gaussian continuous variables. Categorical variables are reported as numbers and proportions.

RESULTS
Participants—numerator: case ascertainment and inclusion
During the observation period, BOSU recorded a card return rate of 77.2%. Clinicians notified BOSU of 270 cases (figure 1). We asked clinicians to complete CRF for 268 babies, excluding one who did not meet the inclusion criteria. To reduce bias from under-reporting, we set up a UK ROP-SIG. Members share an electronic mailing list and can report cases of ROP treatment to the research team electronically; this route led to communication of 165 cases. In total, we received 370 completed forms. We excluded one, as treated outside the observation period, and 42 duplicate reports (same child, reported by different clinicians/units). We included 327 cases in the analysis.
Treatment incidence

Based on the above, the incidence of treatment for ROP during the observation period was 327/8112 or 4% (95% CI 3.6% to 4.5%).

Patient characteristics

Of the included patients, 57.8% were male (table 2); 69.7% were white, 13.8% Asian, 5.5% black, 5.2% mixed and 5.8% other; and 72.8% were singletons, 24.5% twins and 2.1% triplets. Median (IQR) gestational age at birth was 25 weeks (24.3–26.1), and median (IQR) birth weight was 706 g (620–821). Median (IQR) age at first ROP treatment was 80 days (71–96).

Indications for treatment

In the following, we report figures for the right eye; figures for the left eye are similar. At first treatment, 204 right eyes (62.39%) had type 1 ROP, and 27 (8.26%) had AP-ROP (table 3). Type 2 plus ROP was present in 74 right eyes (22.63%), and type 2 in 9 (2.75%). Six (1.83%) had mild ROP. One infant had bilateral, and two had unilateral retinal detachments at first treatment (table 3).

Primary treatment

In 90.5% of right eyes, the first treatment administered was diode laser photoablation of the avascular retina (table 4). One eye received cryotherapy and laser combined (0.3%). Twenty-six infants (8%) received bilateral VEGF inhibitor injections as primary treatment. One child (0.3%) received laser in one and VEGF inhibitor injection in the other eye in the same treatment session, as a vitreous haemorrhage precluded the view of the retina in one eye. Data were missing for three right (0.9%) and six left eyes (1.8%).

Table 2  Demographic, pregnancy and neonatal details of infants requiring ROP treatment

<table>
<thead>
<tr>
<th>Number identified</th>
<th>Gender</th>
<th>327</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female</td>
<td>138 (42.2%)</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>189 (57.8%)</td>
</tr>
<tr>
<td>Ethnic group</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Asian</td>
<td>45 (13.8%)</td>
</tr>
<tr>
<td></td>
<td>Black</td>
<td>18 (5.5%)</td>
</tr>
<tr>
<td></td>
<td>Mixed</td>
<td>17 (5.2%)</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>19 (5.8%)</td>
</tr>
<tr>
<td></td>
<td>White</td>
<td>228 (69.7%)</td>
</tr>
<tr>
<td>Single/multiple birth</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Singleton</td>
<td>238 (72.8%)</td>
</tr>
<tr>
<td></td>
<td>Twin</td>
<td>80 (24.5%)</td>
</tr>
<tr>
<td></td>
<td>Triplet</td>
<td>7 (2.1%)</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>2 (0.6%)</td>
</tr>
<tr>
<td>Birth weight in g, median (IQR)</td>
<td>706 (620–821)</td>
<td></td>
</tr>
<tr>
<td>Gestational age at birth in weeks, median (IQR)</td>
<td>25 (24.3–26.1)</td>
<td></td>
</tr>
<tr>
<td>Age at first ROP treatment in days, median (IQR)</td>
<td>80 (71–96)</td>
<td></td>
</tr>
</tbody>
</table>

ROP, retinopathy of prematurity.

**DISCUSSION**

We present the first systematic evaluation of ROP requiring treatment and current treatment preferences in the UK since the introduction of new treatment recommendations and since the first, unlicensed, use of VEGF inhibitors for this condition.

The primary objectives of this study were to estimate the current incidence of ROP requiring treatment in the UK and physicians' current preference for treatment modalities, including their use of VEGF inhibitors for this condition.

The principal limitation of our study is the case ascertainment methodology, which informs the numerator in our calculation of treatment incidence. The BOSU active surveillance system relies on practitioners notifying a central research office of new cases and to complete CRFs. We sought to maximise case ascertainment by setting up a UK ROP-SIG to optimise stakeholder engagement. The BOSU card return rate (response rate) for the observation period was 77.2%. SIG provided notification of 165 cases. Most but not all of the cases notified via the SIG were formally reported by CRFs. Over the same period, the National Neonatal Audit Programme (NNAP), to which most neonatal units in England and Wales contribute, recorded 321 infants receiving treatment for ROP (personal communication, Daniel Grey, Data Analyst, NNAP). The geographic area covered by our study included England and Wales, and Scotland and Northern Ireland. We recorded 292 infants reported by units in England and Wales, 19 from Scotland and 16 from Northern Ireland. There are two possible explanations for the lower number of treatment cases in England and Wales we observed in comparison to NNAP: either our study delivered an underestimate, or NNAP data are an overestimate. During our study period, there was a 77.2% response rate to BOSU. It would seem plausible that cards were more often returned when babies were observed, but we have no evidence to support this. It is possible therefore that cases were omitted. However, our electronic SIG picked up babies who were not reported via the BOSU cards, so we believe that this would mitigate any under-reporting by BOSU. An alternative explanation for the discrepancy is that data entry onto the NNAP database by non-opthalmic staff may erroneously have recorded ROP screening visits as ROP treatment episodes, leading to an overestimate of treatment numbers.

As denominator, we selected infants born with a birth weight of less than 1500 g. ROP screening criteria include a second item to define the infant at risk, that is, birth before 32 weeks gestational age. However, figures by gestational age are not routinely captured and so our denominator will have excluded the small number of babies who are born before 32 weeks but weigh more than 1500 g. This approach is consistent with other publications. Unfortunately, figures of infants with LBW are not reported throughout the area we surveyed, and we estimated the proportion of LBW infants in Scotland and Ireland from those reported for England.

Calculated that the incidence of ROP treatment in infants born with birth weight under 1500 g is 4%.

**Table 3** Severity of retinopathy in right and left eyes on the day of first treatment

<table>
<thead>
<tr>
<th>Severity category</th>
<th>Number of right eyes treated (% of 327)</th>
<th>Number of left eyes treated (% of 327)</th>
<th>Same severity in both eyes (% of 327)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP-ROP</td>
<td>27 (8.26)</td>
<td>27 (8.26)</td>
<td>27 (8.26)</td>
</tr>
<tr>
<td>Type 1</td>
<td>204 (62.39)</td>
<td>202 (61.77)</td>
<td>174 (53.21)</td>
</tr>
<tr>
<td>Type 2 plus</td>
<td>74 (22.63)</td>
<td>69 (21.10)</td>
<td>43 (13.56)</td>
</tr>
<tr>
<td>Type 2</td>
<td>9 (2.75)</td>
<td>9 (2.75)</td>
<td>6 (1.83)</td>
</tr>
<tr>
<td>Mild</td>
<td>6 (1.83)</td>
<td>9 (2.75)</td>
<td>2 (0.61)</td>
</tr>
<tr>
<td>Unknown</td>
<td>1 (0.31)</td>
<td>2 (0.61)</td>
<td>0</td>
</tr>
<tr>
<td>Partial retinal detachment</td>
<td>1 (0.31)</td>
<td>3 (0.92)</td>
<td>1 (0.31)</td>
</tr>
</tbody>
</table>

AP-ROP, aggressive posterior retinopathy of prematurity.

**Table 4** Details of primary treatment

<table>
<thead>
<tr>
<th>First treatment n=327</th>
<th>Right eye (% of 327)</th>
<th>Left eye (% of 327)</th>
<th>Same treatment modality in both eyes (% of 327)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diode laser VEGF inhibitor injection</td>
<td>296 (90.5%)</td>
<td>294 (89.9%)</td>
<td>291 (89.9%)</td>
</tr>
<tr>
<td>Cryotherapy and laser VEGF inhibitor injection plus laser*</td>
<td>1 (0.3%)</td>
<td>1 (0.3%)</td>
<td>0</td>
</tr>
<tr>
<td>Missing data</td>
<td>3 (0.9%)</td>
<td>6 (1.8%)</td>
<td>1 (0.3%)</td>
</tr>
</tbody>
</table>

*Infant who received VEGF inhibitor in one eye and laser treatment in the other in the same treatment session. VEGF, vascular endothelial growth factor.
methodology which included a parental survey, requiring individual consent for study participation. The authors suspected that this led to under-reporting of cases, and they did not present an incidence figure. A report from a single centre in Scotland observed that between 1995 and 2004, 5% of premature infants meeting the UK screening criteria required treatment. Two UK-based studies, which used large national databases of routinely collected data, NNAP and Hospital Episode Statistics, reported significantly lower incidences of ROP requiring treatment (1.5–2%) than our study (4%), probably due to under-reporting, as ophthalmologists were not involved in data collection. The strengths of our approach are high case ascertainment and data completion. Our treatment incidence figure is also comparable with reports from other countries, which report treatment of 1–5% of infants at risk.

An initially surprising finding was that 27% of eyes received treatment for ROP milder than type 1 and AP-ROP, the current treatment threshold. However, the overwhelming majority of these had preplus disease, which we propose to categorise as ‘type 2 plus’ disease: 74 right and 69 left eyes (22.63% and 21.10%, respectively). In fact, previous reports indicate that 70% of those with preplus disease at 33–34 weeks gestational age may progress to requiring laser treatment. Treatment for disease earlier than type 1 is also not a phenomenon limited to our setting; a recent report of practice patterns of US-based ROP experts found that a substantial proportion of premature infants, 9.5%, were treated for ROP milder than type 1, as practitioners were concerned about as vascular dragging, tractional membranes, vitreous haemorrhages or persistent ROP, all of which are not captured by the current ICROP classification. Our study design did not collect this level of detailed information, but it is clear that in the UK, practitioners are concerned particularly about preplus disease, and provide early treatment.

Finally, our study identified 26 infants who received VEGF inhibitor injections as primary and only treatment, and one who received combined VEGF inhibitor and laser treatment. This is the first published national figure for this new treatment modality; it may inform the design of future ROP treatment trials. At present, the medium and longer term safety and efficacy of this approach, that is, risk of recurrence of ROP and effects on cognitive and physical development, are not known, although concerns about neurodevelopmental outcomes and late recurrence are emerging. Some authors advocate their use for zone 1 ROP or AP-ROP, or in cases of systemically unwell infants, poor visibility of the retina, or after failed laser photocoagulation. Research is urgently needed to provide information about safety and efficacy of these treatments, and to integrate them into current treatment algorithms.

The treatment incidence we report is likely to be generalisable to other highly developed countries, where facilities and staff are available to provide high-intensity care for infants born prematurely.

Acknowledgements We wish to thank the British Ophthalmic Surveillance Unit, in particular, Mr Barry Foot, for advice on study design and collection of case notifications. We thank Ms Anneka Tailor for liaising with practitioners across the UK to facilitate data collection and completion of reports, and for maintaining the study database. We thank Mr Zabeer Ahmed for setting up a comprehensive electronic database.


Contributors All authors meet the ICMJE authorship form and have completed the ICMJE authorship form. GWWA, CB, LB, AHD-N, VL and AR developed the study protocol. LB, AHD-N, GWWA and CB secured funding. All authors reviewed and discussed and interpreted the data acquired. WX carried out data analysis. AHD-N drafted the manuscript, which was then critically reviewed and modified by all authors. All authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. The lead author, AHDN, affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Funding The study received funding from the Moorfields Special Trustees (grant ST 14 01 D) and the Birmingham Eye Foundation. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.

Disclaimer The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Competing interests All authors have completed the ICMJE uniform disclosure form and declare that this work was funded by Moorfields Eye Charity and the Birmingham Eye Foundation. There have not been any financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.

Ethics approval The study was approved by the Research Ethics Committee North of Scotland, Aberdeen (13/NS/0059).
REFERENCES